Topic: drug sales

Roche's drugs, new and old, team up for major sales

Wednesday, April 17, 2019

Last July, Roche put a halt on U.S. price hikes. But that didn't stop five of its products from topping analysts' estimates by double digits in Q1.

4. Novartis

by Angus Liu

To focus as what CEO Vas Narasimhan calls “a medicines company,” Novartis made a series of M&A decisions in 2018.

Roche grew sales by 7% in 2018, even as biosimilar rivals unleashed damage in Europe. But 2019 will be the moment of truth for the Swiss drugmaker. U.S. copycats to its trio of cancer megablockbusters—Herceptin, Rituxan and Avastin—are expected to arrive.

Dupixent and vaccines bring Sanofi back to growth

by Angus Liu

Wednesday, October 31, 2018

Dupixent grew sales by 28% sequentially at constant currencies, to €225 million, and that doesn't even count a recent major approval in asthma.

Bankruptcy looms for bruised Trulance maker Synergy

by Angus Liu

Friday, October 26, 2018

With its Trulance launch on the skids, Synergy is running out of cash and needs to win new debt terms to avoid bankruptcy.

Alexion crowns myasthenia gravis as best-ever Soliris launch

by Angus Liu

Wednesday, October 24, 2018

With its new use in gMG, Soliris volume grew 24% year-over-year to a third-quarter haul of $888 million.

FDA hands Novartis a canakinumab rejection

by Angus Liu

Thursday, October 18, 2018

Novartis is raising its 2018 sales outlook, but canakinumab won’t help it hit the new target—at least not in the cardiovascular sales department.

Roche insists its new drugs will outgrow U.S. biosim erosion

by Angus Liu

Wednesday, October 17, 2018

Roche’s blockbuster cancer trio held their ground so far this year despite biosimilar rivals in the EU, thanks to growth in the U.S. and China.

Awaiting Zytiga patent decision, J&J touts pharma growth

by Eric Sagonowsky

Tuesday, October 16, 2018

J&J could suffer a big patent loss for Zytiga, but even if that happens, the company argues it can grow faster than its peers.

GSK's respiratory franchise takes a big hit with Nucala rebuff

by Tracy Staton

Monday, September 10, 2018

GSK's Nucala took a big hit Friday when the FDA stiff-armed its hoped-for new approval in COPD, which could have boosted sales significantly.